High-yielding, two-step 18F labeling strategy for 18F-PARP1 inhibitors.

Positron emission tomography (PET) of labeled metabolites, drugs, proteins and nanomaterials is rapidly emerging as a powerful imaging tool to detect and monitor the stages of disease, to study human biology, to investigate pharmacokinetics and pharmacodynamics of new drugs, or to measure treatment efficacy in clinical trials. F is one of the most commonly… CONTINUE READING